240 related articles for article (PubMed ID: 18343945)
1. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Schönleben F; Qiu W; Remotti HE; Hohenberger W; Su GH
Langenbecks Arch Surg; 2008 May; 393(3):289-96. PubMed ID: 18343945
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
Schönleben F; Qiu W; Ciau NT; Ho DJ; Li X; Allendorf JD; Remotti HE; Su GH
Clin Cancer Res; 2006 Jun; 12(12):3851-5. PubMed ID: 16778113
[TBL] [Abstract][Full Text] [Related]
3. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.
Schönleben F; Qiu W; Bruckman KC; Ciau NT; Li X; Lauerman MH; Frucht H; Chabot JA; Allendorf JD; Remotti HE; Su GH
Cancer Lett; 2007 May; 249(2):242-8. PubMed ID: 17097223
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
[TBL] [Abstract][Full Text] [Related]
5. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
[TBL] [Abstract][Full Text] [Related]
6. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
7. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
[TBL] [Abstract][Full Text] [Related]
8. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
9. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.
Garcia-Carracedo D; Turk AT; Fine SA; Akhavan N; Tweel BC; Parsons R; Chabot JA; Allendorf JD; Genkinger JM; Remotti HE; Su GH
Clin Cancer Res; 2013 Dec; 19(24):6830-41. PubMed ID: 24132918
[TBL] [Abstract][Full Text] [Related]
10. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
11. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T
Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH
Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503
[TBL] [Abstract][Full Text] [Related]
14. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms.
Xiao HD; Yamaguchi H; Dias-Santagata D; Kuboki Y; Akhavanfard S; Hatori T; Yamamoto M; Shiratori K; Kobayashi M; Shimizu M; Fernandez-Del Castillo C; Mino-Kenudson M; Furukawa T
J Pathol; 2011 Aug; 224(4):508-16. PubMed ID: 21547907
[TBL] [Abstract][Full Text] [Related]
16. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
17. [Pancreatic tumor: progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN); 2. Pathology and pathobiology].
Furukawa T; Kuboki Y; Hatori T; Yamamoto M; Shibata N; Shiratori K
Nihon Naika Gakkai Zasshi; 2012 Jan; 101(1):57-63. PubMed ID: 22413462
[No Abstract] [Full Text] [Related]
18. Familial Intraductal Papillary Mucinous Neoplasm Associated With the Germline MSH6 Missense Variant and Progression of Pancreatic cancer.
Tezuka K; Yamakawa M; Murakami R; Hirai I; Toya R; Suzuki A; Kawamura H; Miyano Y; Sato H; Motoi F
Pancreas; 2024 Jul; 53(6):e476-e486. PubMed ID: 38416847
[TBL] [Abstract][Full Text] [Related]
19. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
20. GNAS and KRAS mutational analyses of intraductal papillary neoplasms of the pancreas and bile duct developing in the same individual: A case report.
Date K; Ohtsuka T; Fujimoto T; Gotoh Y; Nakashima Y; Kimura H; Matsunaga T; Mori Y; Mochidome N; Miyazaki T; Oda Y; Tanaka M; Nakamura M
Pancreatology; 2015; 15(6):713-6. PubMed ID: 26506885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
